Prostaglandin inhibition and cardiovascular risk: maybe timing really is everything.
Bertagnolli
Monica M
MM
Dana-Farber/Brigham and Women's Cancer Center, Brigham and Women's Hospital, 75 Francis Street, Boston, Massachusetts 02115, USA. mbertagnolli@partners.org
Zauber
Ann G
AG
Solomon
Scott
S
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D016588:Anticarcinogenic Agents / Q000627:therapeutic use; D050197:Atherosclerosis / Q000150:complications; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000517:prevention & control*; D002319:Cardiovascular System / Q000187:drug effects / Q000378:metabolism; D002986:Clinical Trials as Topic; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000517:prevention & control; D011448:Prostaglandin Antagonists / Q000627:therapeutic use*; D011453:Prostaglandins / Q000378:metabolism*; D012306:Risk
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016588:Anticarcinogenic Agents; D052246:Cyclooxygenase 2 Inhibitors; D011448:Prostaglandin Antagonists; D011453:Prostaglandins